CSF1 and neoplasm: In preclinical models, blockade of CSF-1/CSF-1R signaling inhibited recruitment of bone marrow myeloid cells to the tumor during chemotherapy and induced type I interferon response, thereby reversing chemoresistance and sensitizing tumor cells to chemotherapy 1-3.